| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 112.338.058 | 103.268.624 | 92.721.438 | 106.058.226 | 96.948.543 | 70.239.569 | 52.195.292 | 1.195.029 | 216.002 | 0 |
| Total Income - EUR | 113.217.139 | 103.762.162 | 93.310.545 | 107.789.241 | 98.845.217 | 76.240.580 | 55.330.528 | 6.462.380 | 6.826.902 | 7.496.060 |
| Total Expenses - EUR | 108.441.219 | 101.593.586 | 90.508.306 | 102.375.937 | 94.344.963 | 74.599.725 | 51.575.466 | 1.207.122 | -3.812.866 | 1.096.482 |
| Gross Profit/Loss - EUR | 4.775.919 | 2.168.576 | 2.802.239 | 5.413.304 | 4.500.254 | 1.640.854 | 3.755.062 | 5.255.258 | 10.639.769 | 6.399.578 |
| Net Profit/Loss - EUR | 4.026.947 | 1.692.339 | 2.233.184 | 4.580.397 | 3.330.360 | 627.865 | 3.755.062 | 4.900.618 | 9.739.500 | 5.515.658 |
| Employees | 0 | 142 | 142 | 123 | 114 | 97 | 37 | 0 | 1 | 1 |
Check the financial reports for the company - Glaxosmithkline (Gsk) Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 575.321 | 308.401 | 379.248 | 274.033 | 257.406 | 39.391 | 2.105 | 0 | 0 | 0 |
| Current Assets | 127.723.840 | 133.585.223 | 136.204.161 | 139.797.201 | 126.344.055 | 111.856.216 | 105.971.537 | 107.723.889 | 117.264.365 | 122.512.720 |
| Inventories | 24.976.892 | 19.810.221 | 22.174.079 | 22.900.980 | 13.913.046 | 15.858.208 | 0 | 0 | 0 | 0 |
| Receivables | 42.514.538 | 52.258.144 | 56.645.644 | 57.179.277 | 33.503.614 | 30.165.104 | 7.391.113 | 1.199.973 | 4.535.340 | 194.740 |
| Cash | 35.035.560 | 61.516.859 | 57.384.438 | 59.716.944 | 78.927.396 | 65.832.904 | 98.580.424 | 106.523.917 | 112.729.025 | 122.317.981 |
| Shareholders Funds | 114.769.625 | 115.291.471 | 115.573.727 | 118.110.715 | 102.282.806 | 100.971.631 | 102.470.879 | 107.689.413 | 117.102.351 | 121.963.556 |
| Social Capital | 101.914.610 | 100.875.221 | 99.168.241 | 97.348.327 | 95.463.068 | 93.653.313 | 91.576.462 | 91.860.578 | 91.582.016 | 91.070.189 |
| Debts | 9.103.232 | 14.612.181 | 17.026.865 | 17.903.511 | 23.847.512 | 8.832.107 | 3.510.228 | 42.808 | 165.531 | 500.111 |
| Income in Advance | 0 | 0 | 0 | 33.464 | 20.883 | 8.780 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Glaxosmithkline (Gsk) Srl